logo
Plus   Neg
Share
Email

Genentech: Risdiplam Trial Meets Primary Goal In People With Type 2 Or 3 SMA

Genentech, a member of the Roche Group (RHHBY), announced Monday that risdiplam met primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy or SMA.

The Part 2 of the study demonstrated statistically significant improvements in the overall study population of people aged 2-25 years with Type 2 or 3 SMA.

Risdiplam is an investigational, survival motor neuron-2 or SMN2 splicing modifier, designed to durably increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body.

The study met its primary endpoint of change from baseline in the Motor Function Measure 32 or MFM-32 scale after one year of treatment with risdiplam, compared to placebo.

According to the company, no treatment-related safety findings leading to study withdrawal have been seen in any risdiplam trial to date.

The company noted that SUNFISH is the largest placebo-controlled study ever undertaken in Type 2 or 3 SMA patients.

Levi Garraway, chief medical officer and Head of Global Product Development, stated that the positive outcome of this trial is an important milestone for people with Type 2 or 3 SMA, too many of whom remain untreated.

Data from the SUNFISH study will be presented at an upcoming medical congress.

Risdiplam is currently being evaluated in four multicenter trials in people with SMA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca Cola said it has no plans to abandon single-use plastic bottles as its consumers still want to use them. Bea Perez, Coca-Cola's senior vice president for sustainability, told the BBC at the World Economic Forum in Davos that consumers like the single-use plastic bottles as they reseal and are lightweight. The Procter & Gamble Company (PG) reported that its second-quarter core earnings per share rose 14 percent year-on-year, due to lower non-core restructuring charges versus the prior year. Currency-neutral core earnings per share increased 15 percent. Organic sales were up five percent, for the quarter.... While reporting financial results for the fourth quarter on Thursday, JetBlue Airways Corp. (JBLU) provided its financial outlook for the first quarter and the full-year 2020. For the first quarter, the company expects earnings in a range of $0.10 to $0.20 per share. Capacity is expected to increase...
Follow RTT
>